Celltrion’s Herzuma (Herceptin biosimilar) Receives Marketing Approval in Australia

 Celltrion’s Herzuma (Herceptin biosimilar) Receives Marketing Approval in Australia

Celltrion’s Herzuma (Herceptin biosimilar) Receives Marketing Approval in Australia

Shots:
  • Herzuma is first biosimilar approved in Australia for the treatment of early breast cancer, locally advanced or metastatic or advance gastric cancer
  • Including Herzuma Celltrion has three biosimilar for Australia, Remsima for autoimmune disease, Truxima for blood cancer approved in Aug 2015 and April 2018 respectively
  • Celltrion plans to launch Herzuma in Australia after discussing the situation of local market with its subsidiary Celltrion Healthcare
Click here to read full press release/ article | Ref: Celltrion | Image: Forbes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post